1. Home
  2. Azioni
  3. Australia
  4. Australian Stock Exchange
  5. Arovella Therapeutics Limited
  6. Notizie
  7. Altre lingue
    ALA   AU0000182784

AROVELLA THERAPEUTICS LIMITED

(ALA)
  Rapporto
Tempo differito Australian Stock Exchange  -  07:51 28/06/2022
0.0240 AUD   +9.09%
01:04Arovella Therapeutics Limited fornisce un aggiornamento sul Sumatriptan
CI
22/06Il partner di Arovella Therapeutics, STADA, inizia il lancio commerciale del farmaco contro l'insonnia in Australia.
MT
22/06Arovella Therapeutics Limited annuncia il lancio di ZolpiMist in Australia
CI
RiassuntoQuotazioniGraficiNotizieRatingCalendarioSocietąFinanzaConsensusRevisioniDerivati 
RiassuntoTutte le notizieAltre lingueComunicati stampaPubblicazioni ufficialiNotizie del settore
Notizie in altre lingue su AROVELLA THERAPEUTICS LIMITED
01:04Arovella Therapeutics Limited Provides Sumatriptan Update
22/06Arovella Therapeutics Partner STADA Begins Commercial Launch of Insomnia Drug in Austra..
22/06Arovella Therapeutics Limited Announces ZolpiMist Launch Australia
09/06Arovella Therapeutics Adopts WEF Framework for ESG Reporting
08/06AROVELLA THERAPEUTICS: Adopts WEF Framework For ESG Reporting
07/06Arovella Therapeutics Ltd Announces Executive Changes
20/04Arovella Therapeutics Limited Signs Services Agreement with Qimr Berghofer Medical Rese..
05/04Arovella Therapeutics Ltd Announces That the US Patent and Trademark Office Has Accepte..
17/03AROVELLA THERAPEUTICS: Proposed issue of securities - ALA
16/03AROVELLA THERAPEUTICS: Application for quotation of securities - ALA
28/02AROVELLA THERAPEUTICS: Update - Proposed issue of securities - ALA
28/02Arovella Therapeutics Limited Reports Earnings Results for the Half Year Ended December..
01/02Arovella Therapeutics Limited announced that it has received AUD 4.568748 million in fu..
24/01Arovella Therapeutics Limited announced that it expects to receive AUD 4.568748 million..
2021Arovella Therapeutics Secures Licensing Rights for Anti-Cancer Therapy
2021Arovella Therapeutics Ltd Announces Appointment of Elizabeth Stoner as Non-Executive Di..
2021Arovella Therapeutics Ltd Announces Executive Changes
2021SUDA PHARMACEUTICALS: Changes Name to Arovella Therapeutics; Shares Jump 4%
2021SUDA Pharmaceuticals Ltd Announces Chile Ministry of Health Approval Granted to Teva Ph..
2021SUDA Pharmaceuticals Ltd Appoints John Maher to Scientific Advisory Board
2021Suda Pharmaceuticals Ltd Reports Earnings Results for the Full Year Ended June 30, 2021
2021SUDA Pharmaceuticals Ltd Appoints Reuben Benjamin to Scientific Advisory Board
2021Suda Pharmaceuticals Ltd Signs Licence and Distribution Agreement with Stada Pharmaceut..
2021Suda Pharmaceuticals Ltd Provides ZolpiMist Update
2021Suda Pharmaceuticals Ltd Has Enters into Collaborative Research Agreement with Imperial..
2021Suda Pharmaceuticals Ltd Announces Appointment of Dr. Debora Barton as Non-Executive Di..
2021SUDA PHARMACEUTICALS: Raises Nearly $3 Million to Develop Cell Therapy Platform; Shares S..
2021SUDA PHARMACEUTICALS: Acquires License for Cancer Cell Therapy Platform from UK Instituti..
2021Suda Licenses A Novel iNKT Cell Therapy Platform
2021Suda Pharmaceuticals Ltd Appoints Professor Gunnar Birgegård as Scientific Advisory Boa..
2021Suda Pharmaceuticals Ltd Appoints of Dr. Anil K. Sood to its Scientific Advisory Board
2021Suda Pharmaceuticals Ltd Reports Earnings Results for the Half Year Ended December 31, ..
2021SUDA PHARMACEUTICALS: Down 7% as Mitsubishi Tanabe Pharma Singapore Backs Out of ZolpiMis..
2021SUDA Has Agrees to Terminate the Agreement with Mitsubishi Tanabe Pharma Singapore Pte ..
2021Tony Macintyre and Michael Baker to Assume the Role of Chief Technical Officer of Suda ..
2020Suda Pharmaceuticals Ltd Announces Ordesa Feasibility Study Update
2020SUDA PHARMACEUTICALS: Gets R&D Tax Refund
2020Suda Pharmaceuticals Ltd. Receives the Final Report for a Canine Pharmacokinetic Study
2020Suda Pharmaceuticals Ltd Reports Earnings Results for the Full Year Ended June 30, 2020
2020Suda Pharmaceuticals Ltd Announces Executive Changes
2020AYTU BIOSCIENCE: Announces Regulatory Approval of ZolpiMist by Australian Therapeutic Goo..
2020Suda Pharmaceuticals Ltd Appoints Phillip Hains as Joint Company Secretary
2020Suda Pharmaceuticals Ltd Announces Change of Registered Office
2020Suda Pharmaceuticals Ltd Appoints Michael Baker as A Director
2020Suda Pharmaceuticals Ltd Provides Anagrelide Project Update
2020Suda Pharmaceuticals Ltd Receives Grant from Japanese Patent Office for the Application..
2020Suda Pharmaceuticals Ltd Provides Update on ZolpiMist Oral Spray
2020Aytu BioScience Announces Exclusive ZolpiMist License to Commercialize Aytu's Oral Spra..
2020Mitsubishi Tanabe Pharma Korea Co Ltd Enters into Licensing Agreement with Suda Pharmac..
2020Suda Pharmaceuticals Ltd Reports Earnings Results for the Half Year Ended December 31, ..
2019Laboratorios Ordesa, S.L Pharmaceuticals Ltd Signs Co-Development Deal with Laboratorio..
2019SUDA Pharmaceuticals Limited Announces Management Changes
2019Suda Pharmaceuticals Ltd Announces Management Changes
2019SUDA Pharmaceuticals Limited Announces Finalised the Product Development, Licence and S..
2019Suda Pharmaceuticals Ltd Announces Executive Changes
2019Suda Pharmaceuticals Ltd Reports Earnings Results for the Full Year Ended June 30, 2019
2019Suda Pharmaceuticals Ltd Announces Richard Franklin as Project Director
2019SUDA Pharmaceuticals Ltd Announces Zolpimist Clinical Study Results Demonstrating Lingu..
2019Uropean Patent Office Informs Suda That It Intends to Grant Anagrelide Patent
2019Suda Pharmaceuticals Ltd Provides an Update to the ArTiMist® Regulatory
2019Suda Pharmaceuticals Ltd Signs Binding Term Sheet with Cann Pharmaceutical Australia
2019Suda Pharmaceuticals Ltd Enters into Agreements with Two International Specialty Consul..
2019Suda Pharmaceuticals Ltd Announces Cessation of Joseph Daniel Ohayon as Director
2019Suda Pharmaceuticals Ltd Announces Management Changes
2019SUDA Pharmaceuticals Ltd Receives Preliminary Notice of Denial for Marketing Approval o..
2019SUDA Submits Marketing Authorization Application for Zolpimist
2019SUDA Appoints David Simmonds to the Board as a Non-Executive Director
2019Suda Pharmaceuticals Ltd Provides Update on its Development of Anagrelide
2019Suda Pharmaceuticals Ltd Reports Earnings Results for the Half Year Ended December 31, ..
2019Suda Pharmaceuticals Ltd Provides Update on its Development of Anagrelide
2018Suda Signs Licence Agreement with Mitsubishi Tanabe for ZolpiMist
2018Suda Pharmaceuticals Ltd Updates ZolpiMist Insomnia Product Development Market
2018Strides Pharma Global Enters into Licensing Agreement with SUDA Pharma
2018Suda Pharmaceuticals Ltd Appoints Andrew Curtis as Vice President, Effect from 15 Octob..
2018Suda Pharmaceuticals Ltd. Reports Audited Consolidated and Parent Earnings Results for ..
1  2Succ.
Prossimo evento su AROVELLA THERAPEUTICS LIMITED